

# Managing allergic diseases in India require significant changes in health infrastructure

Sujoy Khan<sup>1,2</sup>, Harpal Singh<sup>3</sup>, Esben Eller<sup>4</sup>, Ekansh Sharma<sup>4</sup>, and Anirban Maitra<sup>5</sup>

<sup>1</sup>Journal of Sketching Science

<sup>2</sup>Hull University Teaching Hospitals NHS Trust

<sup>3</sup>Astrazeneca Pharma India Ltd

<sup>4</sup>Thermo Fisher Scientific ImmunoDiagnostics Division

<sup>5</sup>Royal Manchester Children's Hospital

August 20, 2020

## Abstract

The report by Krishna MT and colleagues reveals some of the challenges clinicians face in the management of allergic diseases in the Indian subcontinent, especially with lack of availability of adrenaline auto-injectors, accessibility to validated in-vitro diagnostics, standardized allergens for skin testing and allergen immunotherapy products.

## Hosted file

Comment\_PA1\_full\_manuscript.doc available at <https://authorea.com/users/349864/articles/476712-managing-allergic-diseases-in-india-require-significant-changes-in-health-infrastructure>

## Hosted file

Table 1.doc available at <https://authorea.com/users/349864/articles/476712-managing-allergic-diseases-in-india-require-significant-changes-in-health-infrastructure>